Celiac Disease - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Celiac Disease - Pipeline Review, H2 2018’, provides an overview of the Celiac Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Celiac Disease

- The report reviews pipeline therapeutics for Celiac Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Celiac Disease therapeutics and enlists all their major and minor projects

- The report assesses Celiac Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Celiac Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Celiac Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Calypso Biotech SA

IB Pharmaceuticals Inc

ImmusanT Inc

Intrexon Corp

Takeda Pharmaceutical Co Ltd

Topas Therapeutics GmbH

Zedira GmbH

Amgen Inc

Calypso Biotech SA

IB Pharmaceuticals Inc

ImmusanT Inc

Intrexon Corp

Takeda Pharmaceutical Co Ltd

Topas Therapeutics GmbH

Zedira GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Celiac Disease – Overview

Celiac Disease – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Celiac Disease – Overview

Celiac Disease – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Celiac Disease – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Celiac Disease – Companies Involved in Therapeutics Development

Amgen Inc

Calypso Biotech SA

IB Pharmaceuticals Inc

ImmusanT Inc

Intrexon Corp

Takeda Pharmaceutical Co Ltd

Topas Therapeutics GmbH

Zedira GmbH

Celiac Disease – Drug Profiles

AG-017 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-714 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMY-01 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVX-176 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNZ-2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CALY-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DEN-181 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ERW-1041E – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kuma-010 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kuma-062 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larazotide acetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latiglutenase – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Oncology and Tropical Spastic Paraparesis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nexvax-2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nexvax-3 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein for Celiac Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptides for Celiac Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Celiac Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Celiac Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZED-1227 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZED-754 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Celiac Disease – Dormant Projects

Celiac Disease – Product Development Milestones

Featured News & Press Releases

May 24, 2018: ImmusanT CEO Leslie Williams to Discuss Immunology of Celiac Disease at 2018 BIO International Convention

May 21, 2018: ImmusanT Expands Management Team to Strengthen Financial Operations and Accelerate Clinical Development

May 17, 2018: Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.

May 15, 2018: ImmusanT Welcomes Ken Truitt as Chief Medical Officer

May 15, 2018: ImmusanT Welcomes Ken Truitt, M.D. as Chief Medical Officer

May 09, 2018: Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference

Jan 08, 2018: Cour Pharmaceuticals Receives FDA Fast Track Designation For TIMP-GLIA

Jan 04, 2018: ImmusanT Provides Year-End Update and Outlines Goals for 2018

Nov 28, 2017: ImmusanT Data Shows Up-Dosing Substantially Increases Nexvax2 Dose Levels That Are Safe and Tolerable, Further Supports Phase II Studies

Oct 31, 2017: ImmusanT Presents Clinical Data Supporting Improved Dosing Strategy for Nexvax2 and Explaining Early Gluten-Related Clinical Effects in Celiac Disease

Oct 25, 2017: ImmusanT Announces Acceptance of Late Breaking Celiac Interleukin Data at United European Gastroenterology Week

Oct 12, 2017: ImmusanT to Present New Nexvax2 Dosing Data at United European Gastroenterology Week

Sep 13, 2017: Bioniz Therapeutics Presents Data Demonstrating the Synergistic Effects of Cytokines IL-15 and IL-21 in Celiac Disease Pathogenesis

Sep 11, 2017: ImmusanT Presents Data from Multiple Studies Supporting Continued Development of Nexvax2

Aug 29, 2017: ImmunogenX Announces Publication of New Latiglutenase Analyses in Digestive Disease & Science

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Celiac Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Celiac Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Celiac Disease – Pipeline by Amgen Inc, H2 2018

Celiac Disease – Pipeline by Calypso Biotech SA, H2 2018

Celiac Disease – Pipeline by IB Pharmaceuticals Inc, H2 2018

Celiac Disease – Pipeline by ImmusanT Inc, H2 2018

Celiac Disease – Pipeline by Intrexon Corp, H2 2018

Celiac Disease – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Celiac Disease – Pipeline by Topas Therapeutics GmbH, H2 2018

Celiac Disease – Pipeline by Zedira GmbH, H2 2018

Celiac Disease – Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Celiac Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Celiac Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports